English

设为首页 | 加入收藏 | 联系我们

首页 >> 研究生教育 >> 导师介绍 >> 博士生导师

于海波

时间:2020/7/17 来源: 阅读:13552次


于海波

 

于海波  博士,研究员,博士生导师,课题组长

2005年毕业于北京协和医学院药物研究所,获药理学专业理学博士学位; 2008年至2013年在美国约翰霍普金斯大学医学院神经科学系、离子通道中心进行博士后研究。20143月以引进人才方式加入中国医学科学院药物研究所。 主要围绕疾病相关的离子通道,建立离子通道药物研发平台,发现新颖离子通道药物以及开展小分子调控机制研究。在PNAS British Journal of Pharmacology, Neuropharmacology, ACS chemical neuroscienceACS Chem BiolJ Med Chem Bioorg Med Chem Lett等国际学术期刊共发表文章近20余篇。

联系方式

邮箱:haiboyu@imm.ac.cn

 

教育背景

1994/9 - 1999/7,哈尔滨医科大学,临床医学,学士

1999/9 - 2002/7,哈尔滨医科大学,病理生理学,硕士

2002/9 - 2005/7,中国协和医科大学,药理学,博士

 

工作经历

2005/8-2008/5 北京奥维腾隆生物科技有限公司 项目经理

2008/10-2013/10 美国约翰霍普金斯大学医学院神经科学系、离子通道中心,博士后

2014/3 - 至今 中国医学科学院药物研究所,研究员,课题组长

 

专业研究领域: 离子通道药理学

       围绕神经系统疾病相关的离子通道:

1.      建立离子通道药物筛选评价平台;

2.      开展以离子通道为靶点的新药发现研究;开发靶向癫痫及疼痛等疾病的离子通道靶点药物。

3.      探索离子通道在神经系统疾病发生中的作用。

 

 

近年发表论文:

1.      ShengN., Zheng, H., Li,M., Li, M., Wang,Z., Peng, Y., Yu, H.*, Zhang, J*. 4,5 caffeoylquinic acid and scutellarin, identified by integrated metabolomics and proteomics approach as the active ingredients of Dengzhan Shengmai, act against chronic cerebral hypoperfusion by regulating glutamatergic and GABAergic synapses. Pharmacological Research 152 (2020) 104636.

2.      HuangL.*, DingJ., LiM., Hou, Z., Geng,Y., Li,X. and Yu, H*.Discovery of [1,2,4]-triazolo [1,5-a]pyrimidine-7(4H)-one derivatives as positive modulators of GABAA1 receptor with potent anticonvulsant activity and low toxicity. EUR J MED CHEM. 2020;185:111824.

3.      Feng, JM., Li, M., Zhao, JL., Jia, XN., Liu, JM., Zhang, M., Chen, RD., Xie, KB., Chen, DW., Yu, HB*, Dai, JG*. Three new phenylspirodrimane derivatives with inhibitory effect towards potassium channel Kv1.3 from the fungus Stachybotrys chartarum. J Asian Nat Prod Res. 2019 Sep;21(9):887-894.

4.      Li, M.#, Wu, Y.#, Zou,B., Wang,XL, Li,M. and Yu, HB*. Identification of WB4101, an alpha1-adrenoceptor antagonist, as a sodium channel blocker. Mol Pharmacol. 2018,  94(2):896-906. (#,co-first authors)

5.      Wu, Y#., Zou, B#., Liang, L., Li, M., Tao, Y.-X., Yu, H*., Wang, X*., Li, M*., Loperamide inhibits sodium channels to alleviate inflammatory hyperalgesia, Neuropharmacology. 2017, 117: 282-291.  (#,co-first authors)

6.      YuHB.*, Li, M., Wang, WP., Wang, XL*.  High throughput screening technologies for ion channels. Acta Pharmacol Sin. 2016,37(1):34-43.

7.      YuHB.*, ZouBY.*, WangXL., LiM. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay. Acta Pharmacol Sin. 2016,37(1):111-23.

8.      Yu, H.*, Zou, B., Wang, X., Li, M. Effect of Tyrphostin AG879 on Kv4.2 and Kv4.3 potassium channels. Brit J Pharmacol. 2015, 172(13):3370-82

9.      PetersCJ., YuH., TienJ., JanYN., LiM., JanLY.*.  Four basic residues critical for the ion selectivity and pore blocker sensitivity of TMEM16A calcium-activated chloride channels. Proc Natl Acad Sci U S A. 2015 112(11):3547-52.

10.   DuF., BabcockJJ., YuH., ZouB., LiM*.  Global analysis reveals families of chemical motifs enriched for HERG inhibitors. PLoS One. 2015, 10(2):e0118324.

11.   Yu, H., Lin, Z., Mattmann, M., Zou, B., Terrenoire.C., Zhang, H., Wu, M., McManus, O. B., Kass, R. S., Lindsley, C. W., Hopkins, C. R.*, and Li, M*. Dynamic Subunit Stoichiometry Confers a Progressive Continuum of Pharmacological Sensitivity by KCNQ Channels. Proc Natl Acad Sci U S A 110, 2013,8732-8737.

12.   Zhou, P., Yu, H., Gu, M., Nan, F., Gao, Z*, and Li, M*. PIP2 alters pharmacological selectivity for epilepsy-causing KCNQ channels. Proc Natl Acad Sci U S A   110, 8726-8731, 2013.

13.   Zhang, H.#, Zou, B. #, Yu, H. #, Moretti, A., Wang, X., Yan, W., Babcock, J. J., Bellin, M., McManus, O. B., Tomaselli, G., Nan, F., Laugwitz, K. L., and Li, M*. Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A 2012,109, 11866-11871. (# Cofirst author)

14.   Yu, H., Wu, M., Townsend, S. D., Zou, B., Long, S., Daniels, J. S., McManus, O. B., Li, M*, Lindsley, C. W., and Hopkins, C. R*. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS chem neurosci 2011, 2, 572-577.

15.   Cheung, Y. Y., Yu, H., Xu, K., Zou, B., Wu, M., McManus, O. B., Li, M.*, Lindsley, C. W., and Hopkins, C. R*. Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor. J Med Chem 2012, 55, 6975-6979.

16.   Mattmann, M. E., Yu, H., Lin, Z., Xu, K., Huang, X., Long, S., Wu, M., McManus, O. B., Engers, D. W., Le, U. M., Li, M.*, Lindsley, C. W., and Hopkins, C. R*. Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett  2012, 22, 5936-5941.

17.   Du, F., Yu, H., Zou, B., Babcock, J., Long, S., and Li, M*. hERGCentral: a large database to store, retrieve, and analyze compound-human Ether-a-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay Drug Dev Technol  2011, 9, 580-588.

18.   Wang, H. R. #, Wu, M. #, Yu, H., Long, S., Stevens, A., Engers, D. W., Sackin, H., Daniels, J. S., Dawson, E. S., Hopkins, C. R.,  Lindsley, C. W.*, Li, M.*, and McManus, O. B. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. ACS Chem Biol  2011, 6, 845-856.

19.   Zou, B., Yu, H., Babcock, J. J., Chanda, P., Bader, J. S., McManus, O. B., and Li, M*. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-a-go-go related gene potassium channels. Assay Drug Dev Technol  2010, 8, 743-754.

20.   Yu, HB, Li, ZB, Zhang, HX., and Wang, XL*. Role of potassium channels in Abeta(1-40)-activated apoptotic pathway in cultured cortical neurons. J Neurosci Res 2006, 84, 1475-1484.

21.   周宇,王晓良,于海波*。离子通道作为糖尿病神经性疼痛药物靶点的现状研究。药学学报 Acta Pharmaceutica Sinica 2017, 52 (3): 355 −361

 

专著

1.      Yu, H., and Li, M. High throughput methods for ion channels. Handbook of Ion Channels. Edited by Jie Zheng and Matthew C. Trudeau. CRC Press, Pages 199-210. Print ISBN: 978-1-4665-5140-4. 

2.      Yu, H., Lin, Z., Xu, K., Huang, X., Long, S., Wu, M., McManus, O. B., Engers, J. L., Mattmann, M. E., Engers, D. W., Le, U. M., Lindsley, C. W., Hopkins, C. R., and Li, M. Identification of a novel, small molecule activator of KCNQ1 channels. Probe Reports from the NIH Molecular Libraries Program. PMID:    23762928    [PubMed] , 2012.

3.      Yu, H., Wu, M., Long, S., Hopkins, C. R., Engers, J. L., Townsend, S. D., Lindsley, C. W., McManus, O. B., and Li, M. A small molecule activator of KCNQ2 and KCNQ4 channels. Probe Reports from the NIH Molecular Libraries Program. PMID:    23658954    [PubMed], 2011.

4.      Yu, H., Xu, K., Zou, B., Wu, M., McManus, O. B., Engers, J. L., Cheung, Y. Y., Salovich, J. M., Hopkins, C. R., Lindsley, C. W., and Li, M. Identification of a novel, small molecule inhibitor of KCNQ2 channels. Probe Reports from the NIH Molecular Libraries Program. PMID:    23658963    [PubMed], 2011.

5.      Wu, M., Wang, H., Yu, H., Makhina, E., Xu, J., Dawson, E. S., Hopkins, C. R., Lindsley, C. W., McManus, O. B., and Li, M. A potent and selective small molecule Kir2.1 inhibitor. Probe Reports from the NIH Molecular Libraries Program. PMID: 21433384 [PubMed], 2010.

 

 

 

内部链接
相关链接